<DOC>
	<DOCNO>NCT00462046</DOCNO>
	<brief_summary>Berberine show effective lowering blood sugar level db/db mice anti-dyslipidemia human . These finding test clinical trial . This randomized , double blind , placebo control multi-center study demonstrate berberine effective lower plasma glucose concentration , reduce serum HbA1c anti-dyslipidemia type 2 diabetic patient dyslipidemia .</brief_summary>
	<brief_title>Efficacy Safety Berberine Treatment Diabetes With Dyslipidemia</brief_title>
	<detailed_description>Berberine , natural plant alkaloid , well investigated clinical application treatment diabetes . The present study evaluate efficacy safety berberine treatment type 2 diabetic patient dyslipidemia . 116 patient type 2 diabetes dyslipidemia assign randomized , double-blind , placebo-controlled 4-clinical center study receive berberine ( 1.0g daily ) placebo 3 month . The primary efficacy outcome change plasma glucose serum lipid level . The glucose disposal rate ( GDR ) measure use hyperinsulinemic euglycemic clamp ass insulin resistance randomly select subject 54 patient . The baseline characteristic similar berberine placebo group . After 3 month , fast post load plasma glucose level , HbA1C , triglyceride , total cholesterol LDL-C level significantly reduce berberine group compare placebo group ( p &lt; 0.0001 , p &lt; 0.0001 , p &lt; 0.0001 , p=0.002 , p &lt; 0.0001 p &lt; 0.0001 respectively ) . The GDR significantly increase 3 month berberine ( p=0.037 ) , change find placebo group ( p=0.86 ) . BMI , systolic blood pressure serum IL-6 level significantly reduce treatment berberine group compare placebo group ( p=0.016 , p=0.041 p=0.014 , respectively ) . Our result show berberine effective safe treatment person diabetes dislipidemia . This agent may useful treatment patient type 2 diabetes , could play role treatment metabolic syndrome .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>1 . Age 25 70 year ; 2 . Newly diagnose type 2 diabetes accord 1999 World Health Organization criterion ; 3 . Dyslipidemia TG &gt; 150mg/dL ( 1.70mmol/L ) , and/or TC &gt; 200mg/dL ( 5.16mmol/L ) , and/or LDLC &gt; 100mg/dL ( 2.58mmol/L ) accord National Cholesterol Education Program ’ Adult Treatment Panel III ( NCEP : ATPIII ) without previous treatment . 4 . BMI:19 – 40 kg/m2 . 1 . Moderate severe liver renal dysfunction , psychiatric disease severe infection ; 2 . Severe dysfunction heart，New York Heart Association class ³ Ⅲ phase ; 3 . History acute diabetic complication ; 4 . Pregnancy plan pregnancy . 5 . Present previous use drug treatment diabetes dyslipidemia ; 6 . Fasting plasma glucose &gt; 8mmol/L and/or post load plasma glucose level &gt; 17mmol/L 2week runin .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Berberine</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>